Immunovant IMVT
NASDAQ IMVT
$33.65 -0.13 (-0.38%)
As of: Oct 1, 2026 · 3:59 PM EDT

Immunovant (IMVT) Invested Capital (2018 - 2019)

Updated

Immunovant (IMVT) recorded Invested Capital of $7.64 million in fiscal Q4 2019 (quarter ended Mar 31, 2019), down 7.5% from the prior quarter.

Analysis

Immunovant (IMVT) Invested Capital (2018 - 2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 134.01 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 64.89 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 95.89 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 79.44 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 50.26 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 68.99 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 38.08 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 148.69 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Immunovant 6.97 Bn 6.97 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 7.64 Mn
Dec 31, 2018 8.26 Mn
API Access

Immunovant Invested Capital API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=invested-capital&ticker=IMVT&period=max&api_key=YOUR_API_KEY